Table 1 Select ongoing clinical trials of DLL3-targeted agents in SCLC
Treatment | Setting | Primary outcome | Phase | N | ID |
|---|---|---|---|---|---|
Rovalpituzumab tesirine, cisplatin, etoposide | First line | Safety and PFS | 1 | 28 | NCT02819999 |
Rovalpituzumab tesirine, nivolumab, ipilimumab | Second line | Safety | 1/2 | 42 | NCT03026166 |
Rovalpituzumab tesirine versus topotecan | Second line | OS | 3 | 444 | NCT03061812 |
Rovalpituzumab tesirine, dexamethasone | Maintenance | PFS, OS | 3 | 740 | NCT03033511 |
AMG 757 | Second line | Safety, tolerability, and PK | 1 | 92 | NCT03319940 |
AMG 119 | Second line | Safety and tolerability | 1 | 41 | NCT03392064 |